GSK and CureVac sign £132m deal to develop multi-variant Covid vaccine
by Mark Sweney and Julia Kollewe from Science | The Guardian on (#5DPBS)
Companies hope to have next generation of vaccines against emerging variants by next year
GlaxoSmithKline and Germany's CureVac have reached a 150m (132m) agreement to develop a next generation of Covid-19 vaccines targeting new emerging variants in the pandemic.
The two companies said they plan to work jointly to develop a shot next year that can address multiple emerging variants in one vaccine".
Continue reading...